Dec. 7, 2022

On December 7, 2022,the U.S. Food and Drug Administration (FDA) authorized the initiation of a Phase I clinical trial under IND No. 152226 for SON-DP, Qurgen’s transcription factor-based anti-tumor drug, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy for all solid tumors.